SI1923073T1 - Kombinirano zdravilo ki vsebuje pde-5 inhibitor - Google Patents

Kombinirano zdravilo ki vsebuje pde-5 inhibitor

Info

Publication number
SI1923073T1
SI1923073T1 SI200431750T SI200431750T SI1923073T1 SI 1923073 T1 SI1923073 T1 SI 1923073T1 SI 200431750 T SI200431750 T SI 200431750T SI 200431750 T SI200431750 T SI 200431750T SI 1923073 T1 SI1923073 T1 SI 1923073T1
Authority
SI
Slovenia
Prior art keywords
inhibitor
portal hypertension
prevent
portal
treat
Prior art date
Application number
SI200431750T
Other languages
English (en)
Inventor
Wolfgang Kreisel
Deibert Peter
Original Assignee
Universitaetsklinikum Freiburg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitaetsklinikum Freiburg filed Critical Universitaetsklinikum Freiburg
Publication of SI1923073T1 publication Critical patent/SI1923073T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SI200431750T 2003-06-06 2004-06-03 Kombinirano zdravilo ki vsebuje pde-5 inhibitor SI1923073T1 (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10325813A DE10325813B4 (de) 2003-06-06 2003-06-06 Prophylaxe und/oder Therapie bei der portalen Hypertonie
EP06025229A EP1923073B1 (de) 2003-06-06 2004-06-03 Kombinationsmedikation mit PDE-5-Inhibitor

Publications (1)

Publication Number Publication Date
SI1923073T1 true SI1923073T1 (sl) 2011-11-30

Family

ID=33494881

Family Applications (2)

Application Number Title Priority Date Filing Date
SI200431750T SI1923073T1 (sl) 2003-06-06 2004-06-03 Kombinirano zdravilo ki vsebuje pde-5 inhibitor
SI200430378T SI1635838T1 (sl) 2003-06-06 2004-06-03 Zaviralci fosfodiesteraze tipa 5 za profilakso in/ali terapijo pri portalni hipertenziji

Family Applications After (1)

Application Number Title Priority Date Filing Date
SI200430378T SI1635838T1 (sl) 2003-06-06 2004-06-03 Zaviralci fosfodiesteraze tipa 5 za profilakso in/ali terapijo pri portalni hipertenziji

Country Status (14)

Country Link
US (1) US9278097B2 (sl)
EP (2) EP1635838B1 (sl)
JP (3) JP4557970B2 (sl)
KR (2) KR101233828B1 (sl)
CN (1) CN1871010B (sl)
AT (2) ATE361074T1 (sl)
CY (2) CY1107707T1 (sl)
DE (2) DE10325813B4 (sl)
DK (2) DK1635838T3 (sl)
ES (2) ES2374085T3 (sl)
PL (2) PL1923073T3 (sl)
PT (2) PT1923073E (sl)
SI (2) SI1923073T1 (sl)
WO (1) WO2004108062A2 (sl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2449163C (en) * 2001-05-09 2010-07-13 Bayer Healthcare Ag New use of 2-phenyl-substituted imidazotriazinones
DE10232113A1 (de) * 2002-07-16 2004-01-29 Bayer Ag Vardenafil Hydrochlorid Trihydrat enthaltende Arzneimittel
DE102004023069A1 (de) * 2004-05-11 2005-12-08 Bayer Healthcare Ag Neue Darreichungsformen des PDE 5-Inhibitors Vardenafil
DE102004038328A1 (de) * 2004-08-06 2006-03-16 Bayer Healthcare Ag Neue Verwendungen von 2-Phenyl-substituierten Imidazotriazinon-Derivaten
DE102005001989A1 (de) * 2005-01-15 2006-07-20 Bayer Healthcare Ag Intravenöse Formulierungen von PDE-Inhibitoren
DE102005009241A1 (de) * 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit kontrollierter Bioverfügbarkeit
DE102005009240A1 (de) 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit verbesserten pharmakokinetischen Eigenschaften
RU2369392C2 (ru) * 2005-06-10 2009-10-10 Донг-А Фармасьютикал. Ко., Лтд. Средство для профилактики и лечения заболеваний печени, содержащее производное пиразолопиримидинона
AU2006299232A1 (en) * 2005-09-29 2007-04-12 Bayer Schering Pharma Aktiengesellschaft PDE inhibitors and combinations thereof for the treatment of urological disorders
US8512258B2 (en) * 2005-11-11 2013-08-20 Exalenz Bioscience Ltd. Breath test device and method
WO2008151734A1 (en) * 2007-06-13 2008-12-18 Bayer Schering Pharma Aktiengesellschaft Pde inhibitors for the treatment of hearing impairment
KR102146673B1 (ko) 2012-12-04 2020-08-21 주식회사 아리바이오 포스포디에스테라제 타입 ５ 저해제를 포함하는 신경세포의 아폽토시스 억제용 조성물
US20160317542A1 (en) 2013-12-09 2016-11-03 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto
US11576609B2 (en) 2017-06-30 2023-02-14 Georgia State University Research Foundation, Inc. Noninvasive methods for detecting liver fibrosis
CA3023014C (en) * 2017-11-06 2023-09-26 Stalicla Sa Pharmaceutical composition for treatment of autism
CN110811593A (zh) * 2019-11-07 2020-02-21 天津中医药大学第二附属医院 一种高血压中医证型采取肝血流动力学特点的判别方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2882843B2 (ja) * 1990-03-28 1999-04-12 日本化薬株式会社 門脈圧亢進症改善剤
GB9311920D0 (en) 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
US5973011A (en) * 1994-03-30 1999-10-26 Isis Pharma Gmbh Pharmaceutical preparations and medicaments for the prevention and treatment of endothelial dysfunction
DE19961302A1 (de) * 1999-12-18 2001-06-21 Dresden Arzneimittel Verwendung von Imidazo(1,5-a)-pyrido(3,2-e)-pyrazinonen als duale Inhibitoren der Phosphodiesterase 5 und der Phosphodiesterase 3 zur Therapie der Herzinsuffizienz, von pulmonaler Hypertonie und Gefäßerkrankungen, die mit einer Minderdurchblutung einhergehen
KR20010101603A (ko) 1999-01-20 2001-11-14 노왈드 이미다조[1,5-ａ]-피리도[3,2-ｅ]-피라지논의 약제로서의용도
AU3210500A (en) * 1999-01-22 2000-08-07 Selectus Pharmaceuticals, Inc. Controlling heart rate or blood pressure in patients co-medicated with phosphodiesterase inhibitors for treatment of impotence
US6087362A (en) * 1999-03-16 2000-07-11 Pentech Pharmaceuticals, Inc. Apomorphine and sildenafil composition
US20010003120A1 (en) * 1999-05-14 2001-06-07 M. D. Robert Hines Method for treating erectile dysfunction
FR2796945B1 (fr) * 1999-07-30 2002-06-28 Sod Conseils Rech Applic Nouveaux derives d'hydantoines, de thiohydantoines, de pyrimidinediones et de thioxopyrimidinones, leurs procedes de preparation et leur application a titre de medicaments
IL152925A (en) 1999-10-21 2010-04-15 Pfizer Pharmaceutical preparations for the treatment of neurological disease containing an inhibitor of ring guanizine '3', 5 '- monophosphate phosphodiesterase 5 and one of gabapentin or pregabalin
TWI224966B (en) 1999-11-02 2004-12-11 Pfizer Pharmaceutical composition (I) useful for treating or preventing pulmonary hypertension in a patient
DE10004858A1 (de) * 2000-02-03 2001-08-16 Schering Ag Verwendung von Proteinkinase-Inhibitor-alpha
US20020103117A1 (en) 2000-02-03 2002-08-01 Ralph Knoell Use of protein kinase-inhibitor-alpha
US6476037B1 (en) * 2000-03-23 2002-11-05 The Regents Of The University Of California L-arginine and phosphodiesterase (PDE) inhibitor synergism
WO2002019213A2 (en) 2000-08-30 2002-03-07 Lilly Icos Llc Method for treatment of migraine using pde5 inhibitors
US20020028764A1 (en) * 2000-09-04 2002-03-07 Aarhus Amt. Treatment of acute and chronic liver disease
CA2426674A1 (en) 2000-10-25 2002-05-02 Takeda Chemical Industries, Ltd. Agent for preventing or treating portal hypertension
JP2002201128A (ja) * 2000-10-25 2002-07-16 Takeda Chem Ind Ltd 門脈圧亢進症予防・治療剤
EP1355649A2 (de) 2001-01-31 2003-10-29 MERCK PATENT GmbH Pharmazeutische formulierung enthaltend pyrazolo 4,3-d]pyrimidine und nitrate oder thienopyrimidine und nitrate
BR0206847A (pt) * 2001-02-02 2004-02-25 Pfizer Tratamento do diabete melito
CZ20032350A3 (en) 2001-02-02 2004-03-17 Merck Patent Gmbh PHARMACEUTICAL FORMULATION COMPRISING PYRAZOLO 4,3-d PYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS OR THIENOPYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS
US6338862B1 (en) * 2001-03-26 2002-01-15 Sarfaraz K Niazi Composition and method of use in treating sexual dysfunction using cGMP-specific phosphodiesterase type 5 inhibitors
ATE424414T1 (de) * 2001-06-08 2009-03-15 Sod Conseils Rech Applic Chimere somatostatin-dopamin-analoga
LV12979B (en) * 2001-09-07 2003-05-20 Ivars Kalvins Pharmaceutical composition

Also Published As

Publication number Publication date
JP2010195821A (ja) 2010-09-09
PL1635838T3 (pl) 2007-09-28
CY1107707T1 (el) 2013-04-18
ES2287740T3 (es) 2007-12-16
WO2004108062A3 (de) 2005-03-10
DE10325813A1 (de) 2005-01-05
EP1635838A2 (de) 2006-03-22
KR20120024807A (ko) 2012-03-14
US9278097B2 (en) 2016-03-08
JP5631053B2 (ja) 2014-11-26
JP5757677B2 (ja) 2015-07-29
KR101176110B1 (ko) 2012-08-22
DK1635838T3 (da) 2007-09-10
EP1923073A3 (de) 2008-07-09
PL1923073T3 (pl) 2012-02-29
PT1635838E (pt) 2007-08-10
PT1923073E (pt) 2011-10-04
JP2009280602A (ja) 2009-12-03
WO2004108062A2 (de) 2004-12-16
EP1923073A2 (de) 2008-05-21
CY1111918T1 (el) 2015-11-04
DE502004003694D1 (de) 2007-06-14
US20070004744A1 (en) 2007-01-04
KR20060031614A (ko) 2006-04-12
CN1871010A (zh) 2006-11-29
DK1923073T3 (da) 2011-10-17
KR101233828B1 (ko) 2013-02-14
JP4557970B2 (ja) 2010-10-06
SI1635838T1 (sl) 2007-10-31
DE10325813B4 (de) 2007-12-20
EP1635838B1 (de) 2007-05-02
ATE525074T1 (de) 2011-10-15
EP1923073B1 (de) 2011-09-21
ES2374085T3 (es) 2012-02-13
CN1871010B (zh) 2010-05-26
ATE361074T1 (de) 2007-05-15
JP2006527177A (ja) 2006-11-30

Similar Documents

Publication Publication Date Title
CY1111918T1 (el) Συνδυασμενη φαρμακευτικη αγωγη με αναστολεα της φωσφωδιεστερασης-5
BR0108452A (pt) Inibidores da oxidação parcial de ácido graxo no tratamento de insuficiência cardìaca congestiva
EP1500403A4 (en) MEANS FOR THE PREVENTION / TREATMENT OF DIABETES
EP1541551A8 (en) 2-cyano-4-fluoropyrrolidine derivative or its salt
TR200000129T2 (tr) Yepyeni spiroazabisiklik heterosiklik bileşikler.
PL345151A1 (en) Prodrugs of dipeptidyl peptidase iv inhibitors
NO20063572L (no) Kinazolinditosylatsalt forbindelser
EP1389988A4 (en) CATHETER SYSTEM WITH MOVABLE HEAT EXCHANGER
NZ510920A (en) Use of (S)-3-(aminomethyl)-5-methylhexanoic acid (pregabalin) to treat acute and chronic mania in humans
ATE315558T1 (de) Verbindungen mit cytochrom p450ra1 hemmenden aktivität
NO20015932D0 (no) Fremgangsmåte til å behandle diabetes
NO20026251L (no) Ventilanordning med middels bruddtrykk
EP1438063A4 (en) MODULATION OF PHYSIOLOGICAL PROCESSES AND USEFUL MEANS
DK1037629T3 (da) Kombination af et retinsyremetabolismeblokerende middel og en tocopherol
BR0115881A (pt) Emprego de compostos ciclohexanona substituìdos de 6-dimetilaminometil-1-fenil para a terapia da incontinência urinária
EA200401454A1 (ru) Новая комбинация из обратимо действующих ингибиторов протонного насоса и используемых в терапии дыхательных путей лекарственных веществ, предназначенных для лечения респираторных заболеваний
PL334093A1 (en) Application of comt inhibitors in production of drugs preventing occurence of vascular disorders in case of diabetes
WO2003004046A3 (en) Use of xaa-pro peptidases for the treatment of substance p-related disorders
ZA200102727B (en) Method of treating sickle cell disease or thalassemia.
AU2003230830A1 (en) Treatment of type 1 diabetes before and after expression of predisposition markers
WO2006124544A3 (en) Use of tyrosine kinase inhibitors in the treatment of metabolic disorders
WO2002017905A3 (en) Treatment of burns
HK1075006A1 (en) Use of spirolaxine for the preparation of a medicament treating type 2 insulin-resistant diabetes mellitus
TH52661A (th) ซับสทิทิวเทด บิสอินโดลิลมาเลอิไมด์ สำหรับการยับยั้งการงอกขยายของเซลล์
TH62955B (th) ซับสทิทิวเทด บิสอินโดลิลมาเลอิไมด์ สำหรับการยับยั้งการงอกขยายของเซลล์